Antiviral drugs block replication of highly immune-evasive Omicron subvariants ex vivo, but fail to reduce tissue inflammation

The identification of the SARS-CoV-2 Omicron variants BA.4/BA.5, BF.7 and BQ.1.1 immediately raised concerns regarding the efficacy of currently used monoclonal antibody therapies. Here we examined the activity of monoclonal antibody therapies and antiviral drugs against clinical specimens for SARS-...

Descripción completa

Detalles Bibliográficos
Autores principales: Dichtl, Stefanie, Diem, Gabriel, Jäger, Michael, Zaderer, Viktoria, Lupoli, Gaia, Dächert, Christopher, Muenchhoff, Maximilian, Graf, Alexander, Blum, Helmut, Keppler, Oliver T., Lass-Flörl, Cornelia, Weiss, Günter, Wilflingseder, Doris, Posch, Wilfried
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033493/
https://www.ncbi.nlm.nih.gov/pubmed/36965526
http://dx.doi.org/10.1016/j.antiviral.2023.105581

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033493/
https://www.ncbi.nlm.nih.gov/pubmed/36965526
http://dx.doi.org/10.1016/j.antiviral.2023.105581

Ejemplares similares